JP2007521287A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007521287A5 JP2007521287A5 JP2006517847A JP2006517847A JP2007521287A5 JP 2007521287 A5 JP2007521287 A5 JP 2007521287A5 JP 2006517847 A JP2006517847 A JP 2006517847A JP 2006517847 A JP2006517847 A JP 2006517847A JP 2007521287 A5 JP2007521287 A5 JP 2007521287A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- optionally substituted
- hydrogen
- phenyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 115
- 229910052739 hydrogen Inorganic materials 0.000 claims 113
- 239000001257 hydrogen Substances 0.000 claims 106
- -1 NRSO 2 Inorganic materials 0.000 claims 95
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 87
- 229910052760 oxygen Inorganic materials 0.000 claims 75
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 74
- 125000001931 aliphatic group Chemical group 0.000 claims 69
- 125000003118 aryl group Chemical group 0.000 claims 65
- 229910052757 nitrogen Inorganic materials 0.000 claims 62
- 150000002431 hydrogen Chemical class 0.000 claims 59
- 229910052717 sulfur Inorganic materials 0.000 claims 58
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 56
- 125000005842 heteroatom Chemical group 0.000 claims 51
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 45
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 43
- 239000001301 oxygen Substances 0.000 claims 43
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 41
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 40
- 239000011593 sulfur Substances 0.000 claims 40
- 125000000217 alkyl group Chemical group 0.000 claims 34
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 32
- 125000000623 heterocyclic group Chemical group 0.000 claims 31
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 29
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 28
- 229910052736 halogen Inorganic materials 0.000 claims 25
- 150000002367 halogens Chemical class 0.000 claims 25
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 25
- 125000003386 piperidinyl group Chemical group 0.000 claims 25
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- 125000004429 atom Chemical group 0.000 claims 19
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 17
- 229910052799 carbon Inorganic materials 0.000 claims 17
- 125000006413 ring segment Chemical group 0.000 claims 16
- 150000001721 carbon Chemical group 0.000 claims 15
- 125000005843 halogen group Chemical group 0.000 claims 14
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 14
- 229920006395 saturated elastomer Polymers 0.000 claims 14
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 11
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 10
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 9
- 208000002193 Pain Diseases 0.000 claims 9
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 9
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 8
- 229910052794 bromium Inorganic materials 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 229910052801 chlorine Inorganic materials 0.000 claims 8
- 229910052731 fluorine Inorganic materials 0.000 claims 8
- 125000005936 piperidyl group Chemical group 0.000 claims 8
- 125000000168 pyrrolyl group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000001544 thienyl group Chemical group 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000001041 indolyl group Chemical group 0.000 claims 7
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 6
- 125000004193 piperazinyl group Chemical group 0.000 claims 6
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 5
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 5
- 125000005505 thiomorpholino group Chemical group 0.000 claims 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 125000002971 oxazolyl group Chemical group 0.000 claims 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 208000008035 Back Pain Diseases 0.000 claims 3
- 208000005298 acute pain Diseases 0.000 claims 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 3
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims 3
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 3
- 125000004306 triazinyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000004404 Intractable Pain Diseases 0.000 claims 2
- 206010028836 Neck pain Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 2
- 208000008765 Sciatica Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000015706 neuroendocrine disease Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 claims 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 claims 1
- 0 CC(c1c(C)nc(/C2=C\C=C\C=C\C=C2)nc1N(*)*)=O Chemical compound CC(c1c(C)nc(/C2=C\C=C\C=C\C=C2)nc1N(*)*)=O 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48436203P | 2003-07-02 | 2003-07-02 | |
| US50020003P | 2003-09-04 | 2003-09-04 | |
| PCT/US2004/021440 WO2005003099A2 (en) | 2003-07-02 | 2004-07-02 | Pyrimidines useful as modulators of voltage-gated ion channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007521287A JP2007521287A (ja) | 2007-08-02 |
| JP2007521287A5 true JP2007521287A5 (https=) | 2007-09-13 |
Family
ID=33567720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006517847A Withdrawn JP2007521287A (ja) | 2003-07-02 | 2004-07-02 | 電位依存性イオンチャネルの調節因子として有用なピリミジン |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7816529B2 (https=) |
| EP (1) | EP1638955A2 (https=) |
| JP (1) | JP2007521287A (https=) |
| KR (1) | KR20060032190A (https=) |
| AR (1) | AR045010A1 (https=) |
| AU (1) | AU2004253962A1 (https=) |
| CA (1) | CA2531061A1 (https=) |
| IL (1) | IL172937A0 (https=) |
| MX (1) | MXPA06000051A (https=) |
| NO (1) | NO20060518L (https=) |
| PE (1) | PE20051029A1 (https=) |
| RU (1) | RU2006102955A (https=) |
| TW (1) | TW200519094A (https=) |
| WO (1) | WO2005003099A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200519094A (en) * | 2003-07-02 | 2005-06-16 | Vertex Pharma | Pyrimidines useful as modulators of voltage-gated ion channels |
| GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| EP1863796A1 (en) * | 2005-03-22 | 2007-12-12 | NeuroSearch A/S | Pyrazolyl-pyrimidines as potassium channel modulating agents and their medical use |
| JP2008540443A (ja) * | 2005-05-04 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なピリミジンおよびピラジン |
| WO2006119390A1 (en) * | 2005-05-04 | 2006-11-09 | Vertex Pharmaceuticals Incorporated | Pyridines useful as modulators of ion channels |
| JP5388574B2 (ja) * | 2005-05-31 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なヘテロ環式類 |
| JP2009534458A (ja) | 2006-04-26 | 2009-09-24 | キャンサー・リサーチ・テクノロジー・リミテッド | アミノ−エチル−アミノ−アリール（ａｅａａ）化合物およびそれらの使用 |
| WO2007146284A2 (en) * | 2006-06-12 | 2007-12-21 | Vertex Pharmaceuticals Incorporated | Thienopyrimidines useful as modulators of ion channels |
| EP2132196A1 (en) | 2007-02-26 | 2009-12-16 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| WO2008110891A2 (en) * | 2007-03-09 | 2008-09-18 | Orchid Research Laboratories Limited, | New heterocyclic compounds |
| KR101547705B1 (ko) | 2007-05-22 | 2015-08-26 | 와이어쓰 엘엘씨 | 히드라지드의 개선된 제조 방법 |
| JP2009007273A (ja) * | 2007-06-27 | 2009-01-15 | Ajinomoto Co Inc | ジアミノピリミジン化合物の製造方法 |
| US20090054392A1 (en) * | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| WO2009049157A1 (en) * | 2007-10-11 | 2009-04-16 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
| DE102007061756A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung |
| JP2011510996A (ja) * | 2008-01-30 | 2011-04-07 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびその使用 |
| WO2009097475A1 (en) * | 2008-01-30 | 2009-08-06 | Smithkline Beecham Corporation | NOVEL sEH INHIBITORS AND THEIR USE |
| US20100311776A1 (en) * | 2008-01-30 | 2010-12-09 | Smithkline Beecham Corporation | Novel sEH Inhibitors and their Use |
| US20090198057A1 (en) * | 2008-02-05 | 2009-08-06 | Pu-Ping Lu | Certain Chemical Entities, Compositions, and Methods |
| US8536185B2 (en) | 2008-09-22 | 2013-09-17 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
| AR075196A1 (es) * | 2009-02-03 | 2011-03-16 | Otsuka Pharma Co Ltd | Un derivado de cianopirimidina para el tratamiento de una enfermedad ocular |
| TW201139406A (en) * | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
| PT2616465E (pt) * | 2010-09-13 | 2016-03-09 | Novartis Ag | Triazino-oxadiazoles |
| CA2840883C (en) * | 2011-07-07 | 2019-07-16 | Merck Patent Gmbh | Substituted azaheterocycles |
| TW201706265A (zh) | 2015-03-09 | 2017-02-16 | 必治妥美雅史谷比公司 | 做為Ｒｈｏ激酶（ＲＯＣＫ）抑制劑之內醯胺 |
| GB201721751D0 (en) * | 2017-12-22 | 2018-02-07 | Adorx Therapeutics Ltd | Compounds |
| EP4320103A1 (en) * | 2021-04-09 | 2024-02-14 | Quanta Therapeutics, Inc. | Pyrimidine based ras modulators and uses thereof |
| EP4452253A4 (en) * | 2021-12-23 | 2026-04-15 | The Katholieke Univ Leuven | 2-PYRAZOLE, ANILINES AND RELATED ANALOGUES TO INHIBIT YAP/TAZ-TEAD |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| KR20260041941A (ko) | 2023-03-15 | 2026-03-27 | 콴타 테라퓨틱스, 인크. | Kras 조절 인자 및 이의 용도 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB901749A (en) | 1957-12-06 | 1962-07-25 | Ciba Ltd | New 2-substituted pyrimidines |
| US3040047A (en) * | 1960-04-04 | 1962-06-19 | Takeda Pharmaceutical | 2-(pyrazol-1-yl)-pyrimidine derivatives |
| US3850928A (en) * | 1969-11-04 | 1974-11-26 | American Home Prod | Substituted 6-alkylamino-2-phenyl-5-pyrimidine carboxylic acids |
| US3759922A (en) * | 1971-06-25 | 1973-09-18 | American Home Prod | Preparation of pyrimido(5,4-c)(1,5) benz oxazepin-5(11h)-ones and intermediates |
| US3850931A (en) * | 1971-06-25 | 1974-11-26 | American Home Prod | 4-(substituted anilino)-2-phenyl-5-pyrimidinecarboxylic acid esters |
| US3860596A (en) * | 1972-08-31 | 1975-01-14 | American Home Prod | 2-aryl-4-substituted-amino-5-pyrimidyl derivatives |
| DE2341925A1 (de) * | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
| FR2263750A1 (en) | 1974-03-12 | 1975-10-10 | Delalande Sa | N-phenyl-N-(2-aryl-6-methyl-pyrimidin-4-yl)amino acid derivs. - useful e.g. as analeptics, hypotensives, analgesics, etc. |
| FR2281117A2 (fr) * | 1974-08-09 | 1976-03-05 | Ugine Kuhlmann | Nouvelles piperazino-pyrimidines utilisables comme medicaments |
| JPS6044303B2 (ja) * | 1975-02-25 | 1985-10-02 | 大日本製薬株式会社 | ２−環状アミノ−４−アミノピリミジン誘導体の製造法 |
| WO1987004928A1 (fr) * | 1986-02-24 | 1987-08-27 | Mitsui Petrochemical Industries, Ltd. | Agents therapeutiques de la neuropathie |
| CZ20032233A3 (cs) * | 2001-02-20 | 2004-12-15 | Bristol-Myers Squibb Company | Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ |
| AU2003229305A1 (en) * | 2002-05-17 | 2003-12-02 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS |
| TW200519094A (en) * | 2003-07-02 | 2005-06-16 | Vertex Pharma | Pyrimidines useful as modulators of voltage-gated ion channels |
| JP2008540443A (ja) * | 2005-05-04 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なピリミジンおよびピラジン |
-
2004
- 2004-07-02 TW TW093120064A patent/TW200519094A/zh unknown
- 2004-07-02 RU RU2006102955/04A patent/RU2006102955A/ru not_active Application Discontinuation
- 2004-07-02 KR KR1020067000095A patent/KR20060032190A/ko not_active Ceased
- 2004-07-02 WO PCT/US2004/021440 patent/WO2005003099A2/en not_active Ceased
- 2004-07-02 MX MXPA06000051A patent/MXPA06000051A/es unknown
- 2004-07-02 JP JP2006517847A patent/JP2007521287A/ja not_active Withdrawn
- 2004-07-02 AR ARP040102352A patent/AR045010A1/es unknown
- 2004-07-02 CA CA002531061A patent/CA2531061A1/en not_active Abandoned
- 2004-07-02 US US10/884,865 patent/US7816529B2/en not_active Expired - Fee Related
- 2004-07-02 PE PE20050002102004000638A patent/PE20051029A1/es not_active Application Discontinuation
- 2004-07-02 AU AU2004253962A patent/AU2004253962A1/en not_active Abandoned
- 2004-07-02 EP EP04777512A patent/EP1638955A2/en not_active Withdrawn
-
2006
- 2006-01-02 IL IL172937A patent/IL172937A0/en unknown
- 2006-02-01 NO NO20060518A patent/NO20060518L/no not_active Application Discontinuation
-
2010
- 2010-09-08 US US12/877,793 patent/US8324220B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007521287A5 (https=) | ||
| RU2006102955A (ru) | Пиримидины, пригодные в качестве модуляторов потенциалзависимых ионных каналов | |
| AU2021204556B2 (en) | Compounds and methods for the targeted degradation of androgen receptor | |
| AU2019283921B2 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| ES2360933T3 (es) | Derivados de heteroarilo condensados. | |
| CN114025755B (zh) | 以杂环化合物作为激酶抑制剂的治疗用途 | |
| JP2020050665A (ja) | Ｔｒｋキナーゼ阻害剤としての置換イミダゾ［１，２ｂ］ピリダジン化合物 | |
| JP2023505258A5 (https=) | ||
| JP2022506887A (ja) | 窒素含有縮合複素環系ｓｈｐ２阻害剤化合物、製造方法及び使用 | |
| AU2007231362B2 (en) | Imidazo [1, 2-b] pyridazines, their processes of preparation and their use as GABA receptor ligands | |
| JP2012512886A5 (https=) | ||
| TW202327591A (zh) | Parp抑制劑、包含其的藥物組合物及其用途 | |
| KR20140138911A (ko) | Ｍｅｋ 억제제로서 헤테로사이클릴 화합물 | |
| KR20170069199A (ko) | 섬유 아세포 성장 인자 수용체 키나아제 억제제인 인다졸계 화합물 및 이의 제조와 응용 | |
| JP2019535689A5 (https=) | ||
| RU2011110908A (ru) | Тиенопиримидины для фармацевтических композиций | |
| AU2007338754A1 (en) | 5-cyan0-4- (pyrrolo [2, 3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors | |
| RU2018131539A (ru) | Соединение мочевины, способ его получения и его медицинское применение | |
| JP2021514346A (ja) | 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼｍｋｋ４阻害剤 | |
| JP2021529815A (ja) | 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼ阻害剤 | |
| JP2013533868A (ja) | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 | |
| CA2724215C (en) | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs | |
| JP2021514011A5 (https=) | ||
| KR20110028445A (ko) | 퇴행성 및 염증성 질병의 치료에 유용한 축합된 피라진 화합물 | |
| ES2439918T3 (es) | Compuestos de 1H-tieno[2,3-c]-pirazol útiles como inhibidores de cinasas |